Key Takeaways Sandisk Corporation (SNDK) is benefiting from a structural shift in enterprise solid-state drive demand as AI workloads redefine storage priorities inside data centers. Customers are no longer optimizing only for cost per gigabyte. AI inference and large-scale data processing require low latency, higher throughput and dependable endurance. This evolution shifts competition away from pure pricing toward performance capability. For Sandisk, this transition is strengthening pricing power while de ...

Core Insights - Johnson & Johnson's (JNJ) MedTech segment, which includes products in orthopedics, surgery, cardiovascular, and vision markets, represents approximately 36% of the company's total revenues, achieving nearly $34 billion in sales in 2025 with a 5.4% operational growth supported by 15 major new product launches [1][10] MedTech Segment Performance - J&J is transitioning its MedTech portfolio towards high innovation and high growth markets, particularly in Cardiovascular, with sales in this segment increasing by 15.8% to $8.9 billion in 2025 due to acquisitions of Shockwave and Abiomed [2][10] - The MedTech business has shown improvement over the last three quarters, driven by the acquired cardiovascular businesses and growth in Surgical Vision and wound closure, resulting in a 4.3% organic sales increase in 2025 [3][10] Challenges and Future Outlook - The company faces challenges in China due to the volume-based procurement (VBP) program, which is impacting sales growth in some MedTech areas [4] - For 2026, J&J anticipates better growth in the MedTech business compared to 2025, driven by the adoption of new products across its portfolios, although it expects continued VBP impacts in China and potential tariff costs of around $500 million [5][10] Strategic Developments - J&J is considering separating its Orthopaedics franchise into a standalone company, DePuy Synthes, by mid-2027, which is expected to enhance growth and margins for its MedTech unit in the long term [6] Competitive Landscape - J&J's MedTech unit competes with major players in the medical device industry, including Medtronic, Abbott, Stryker, and Boston Scientific, each specializing in various medical technologies [7][8] Stock Performance and Valuation - J&J's stock has outperformed the industry over the past year, rising 55.9% compared to the industry's 21.3% increase [9] - The company's shares are currently trading at a price/earnings ratio of 20.90, which is higher than the industry average of 18.83 and above its five-year mean of 15.65 [12] Earnings Estimates - The Zacks Consensus Estimate for J&J's 2026 earnings has increased from $11.47 to $11.54, while the estimate for 2027 has risen from $12.25 to $12.40 over the past 30 days [14]

Core Viewpoint - Goldman Sachs (GS) has shown a downtrend recently, losing 5.9% over the past four weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom in a downtrend, characterized by a small candle body and a long lower wick, suggesting that bears may be losing control [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There has been an upward trend in earnings estimate revisions for GS, which is a bullish indicator suggesting potential price appreciation [7]. - The consensus EPS estimate for the current year has increased by 1.1% over the last 30 days, indicating analysts' agreement on improved earnings potential [8]. - GS currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - ServisFirst Bancshares, Inc. (SFBS) is showing potential for bullish momentum due to a recent technical indicator known as a "golden cross" [1] Technical Analysis - SFBS's 50-day simple moving average has recently crossed above its 200-day moving average, indicating a potential bullish breakout [1] - A golden cross typically signifies a trend reversal from a downtrend to an upward trajectory, consisting of three stages: a downtrend, the crossover of moving averages, and an upward price movement [2] Performance Metrics - Over the last four weeks, SFBS has increased by 10.1%, suggesting strong upward momentum [3] - The company currently holds a 1 (Strong Buy) rating on the Zacks Rank, indicating positive investor sentiment [3] Earnings Expectations - There have been two upward revisions in earnings expectations for the current quarter, with no downward revisions, further supporting the bullish outlook [3] - The Zacks Consensus Estimate for earnings has also increased, reinforcing confidence in the company's growth potential [3][4] Investment Outlook - With favorable earnings estimate revisions and a key technical breakout, SFBS is positioned for potential gains in the near future [4]

Shares of Calix (CALX) have been struggling lately and have lost 8.2% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the ...

Shares of Stantec (STN) have been struggling lately and have lost 14.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings o ...

Core Viewpoint - Adyen N.V. Unsponsored ADR (ADYEY) has experienced a bearish trend, losing 20.2% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom in a downtrend, characterized by a small candle body and a long lower wick, suggesting that bears may be losing control [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There is rising optimism among Wall Street analysts regarding ADYEY's future earnings, with a 1.3% increase in the consensus EPS estimate over the last 30 days, indicating improved earnings potential [7][8]. - ADYEY holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [9][10].

Investors who purchased or otherwise acquired shares of REGENXBIO should contact the Firm prior to the April 14, 2026 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-l ...

The move is said to be in response to the higher taxes and rising costs that impacted the UK pub sector. The company, which operates around 2,600 pubs across Britain, is considering changes that may affect around 100 roles in its head office and central teams. Discussions are ongoing, and no final decision is believed to have been made. The company has declined to comment on the report. This latest review follows a significant restructuring less than two years ago, when Greene King cut head office and field ...

GlebStock/Shutterstock.com JFrog (FROG) Gains Momentum Following 26% Revenue Growth Beat Wasatch Global Investors, an asset management company, released its "Small Cap Growth Strategy" Q4 2025 investor letter. A copy of the letter can be downloaded here. The Wasatch Small Cap Growth Strategy experienced a challenging fourth quarter as small-cap equities lagged broader market indices, reflecting investor caution and a continued preference for larger, more liquid stocks. During the period, the Russell 2000® G ...